We are thrilled to share some exciting updates from Ventis Pharma’s recent participation in two prestigious medical conferences, the ASRA and COA conferences. These events have been pivotal in showcasing our groundbreaking product, the Endura-KT™, to a captivated audience of medical professionals. In this blog post, we will recap the highlights from these conferences and the promising prospects that lie ahead for Ventis Pharma.

ASRA Conference, March 31st-April 2^nd 2022:

Ventis Pharma had a remarkable presence at the ASRA (American Society of Regional Anesthesia and Pain Medicine) conference, held in Las Vegas. We extend our heartfelt gratitude to the dedicated team members who represented us at this event. The ASRA conference proved to be a tremendous success, with a resounding interest from anesthesiologists who are eager to incorporate Endura-Kit™ into their practice.

The buzz generated by Endura-KT™ at the ASRA conference was truly inspiring. Anesthesiologists recognized the significant impact our product can bring to the medical field, and the level of interest it garnered was unparalleled. Notably, several other medical companies expressed interest in representing our product, highlighting the widespread appeal of Endura-Kit™ among industry professionals.

COA Conference, April 7th-April 9^th 2022:

Following our success at ASRA, Ventis Pharma continued its winning streak at the COA (California Orthopedic Association) conference in Indian Wells. Our team members showcased the unique formulation of Endura-KT™ and its potential to revolutionize patient outcomes in orthopedic surgery. The response from California orthopedic surgeons was nothing short of exceptional, as they expressed a deep intrigue in the product and its benefits.

Ventis Pharma is proud to acknowledge the excellent work of our team members at the COA conference. Their efforts resulted in significant interest and engagement with medical professionals who see the immense potential of Endura-KT™ in enhancing patient care in the orthopedic field.

Future Prospects:

The success at both ASRA and COA conferences has opened exciting doors for Ventis Pharma. We are delighted to announce that we are currently in the process of scheduling trials and usage studies for our product. The overwhelming interest and positive feedback received at these events have underscored the importance of advancing Endura-KT™ in the medical community.

As we move forward, Ventis Pharma remains committed to pushing the boundaries of medical innovation. We are dedicated to ensuring that Endura-KT™ reaches its full potential in improving patient outcomes and setting new standards in the healthcare industry.


Ventis Pharma’s remarkable achievements at the ASRA and COA conferences are a testament to our commitment to innovation and excellence. We extend our gratitude to our dedicated team members and express our excitement for the journey ahead as we continue to make a positive impact on the healthcare landscape.